ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014
p38 MAPK in pancreatic cancer: finding a protective needle in the haystack.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- M1 Macrophage-derived TNF-α Promotes Pancreatic Cancer Ferroptosis via p38 MAPK-ACSL4 Pathway.Current molecular medicine · 2026Article
- Apoptotic Effect of Gallic Acid via Regulation of p-p38 and ER Stress in PANC-1 and MIA PaCa-2 Cells Pancreatic Cancer Cells.International journal of molecular sciences · 2023Article
- A novel P38α MAPK activator Bruceine A exhibits potent anti-pancreatic cancer activity.Computational and structural biotechnology journal · 2021Article
- Requirement for epithelial p38α in KRAS-driven lung tumor progression.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma.Cancer cell international · 2019Article
- TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression.Nature communications · 2018Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Activated p38 MAPK alpha (pp38α) is a good prognostic marker in pancreatic ductal adenocarcinoma that could be used to personalize therapy. pp38α suppresses JNK-mediated proliferation, both in vitro and in vivo. These findings support the testing of combination therapies that include JNK targeting and/or suppressing negative regulators of pp38α.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.